文献速递心脑血管急症

早期节律控制治疗在房颤患者中的应用

Early Rhythm-Control Therapy in Patients with Atrial Fibrillation.
PubMed 文献 · N Engl J Med · 2020-08-29
一句话结论早期房颤合并心血管疾病患者,早期节律控制较常规治疗降低心血管不良结局风险(HR 0.79)。

EAST-AFNET 4是一项国际、研究者发起、平行组、开放、盲法终点评估试验,纳入诊断≤1年的早期房颤合并心血管疾病患者2789例,随机接受早期节律控制(抗心律失常药物或房颤消融)或常规治疗(仅针对症状控制节律)。中位随访5.1年,早期节律控制组主要终点(心血管死亡、卒中、心衰恶化或急性冠脉综合征住院)发生249例(3.9/100人年),常规治疗组316例(5.0/100人年),HR 0.79(96%CI 0.66-0.94;P=0.005)。两组每年住院夜数无显著差异(5.8±21.9 vs 5.1±15.5天;P=0.23),主要安全性终点无显著差异,但节律控制相关严重不良事件在早期节律控制组4.9%、常规治疗组1.4%。结论:早期房颤合并心血管疾病患者,早期节律控制与较低心血管不良结局风险相关。

要点

  • 早期房颤(诊断≤1年)合并心血管疾病患者,早期节律控制组主要终点事件249例(3.9/100人年),常规治疗组316例(5.0/100人年),HR 0.79(96%CI 0.66-0.94;P=0.005)。
  • 两组每年住院夜数无显著差异:早期节律控制组5.8±21.9天 vs 常规治疗组5.1±15.5天(P=0.23)。
  • 节律控制相关严重不良事件:早期节律控制组4.9% vs 常规治疗组1.4%。
  • 2年时症状和左心室功能两组无显著差异;主要安全性终点事件百分比两组无显著差异。

适用人群与场景

  • 诊断≤1年的早期房颤合并心血管疾病的患者;中位诊断至入组时间36天。

处置流程与药物剂量

  • 早期节律控制包括随机分组后接受抗心律失常药物治疗或房颤消融;常规治疗仅将节律控制限于管理房颤相关症状。

研究设计与关键结果

  • 国际、研究者发起、平行组、开放、盲法终点评估试验,135个中心,2789例早期房颤患者随机分组,中位随访5.1年。
  • 主要终点(心血管死亡、卒中、心衰恶化或急性冠脉综合征住院)事件:早期节律控制组249例(3.9/100人年) vs 常规治疗组316例(5.0/100人年),HR 0.79(96%CI 0.66-0.94;P=0.005)。
  • 每年住院夜数:早期节律控制组5.8±21.9天 vs 常规治疗组5.1±15.5天,无显著差异(P=0.23)。
  • 主要安全性终点事件百分比两组无显著差异;节律控制相关严重不良事件早期节律控制组4.9% vs 常规治疗组1.4%。
  • 2年时症状和左心室功能两组无显著差异。

证据类型、等级与局限

  • 证据类型:随机对照试验(RCT);试验因疗效在第三次中期分析后提前终止。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于早期房颤(诊断≤1年)合并心血管疾病的患者,早期节律控制(抗心律失常药物或房颤消融)较常规治疗可降低心血管不良结局风险(HR 0.79)。
  • 早期节律控制组节律控制相关严重不良事件发生率为4.9%,常规治疗组为1.4%。
  • 早期节律控制未显著减少每年住院夜数,两组2年时症状和左心室功能无显著差异。

指南或共识出处

  • EAST-AFNET 4试验(ISRCTN04708680;ClinicalTrials.gov NCT01288352;EudraCT 2010-021258-20),由德国联邦教育与研究部等资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Despite improvements in the management of atrial fibrillation, patients with this condition remain at increased risk for cardiovascular complications. It is unclear whether early rhythm-control therapy can reduce this risk.

METHODS: In this international, investigator-initiated, parallel-group, open, blinded-outcome-assessment trial, we randomly assigned patients who had early atrial fibrillation (diagnosed ≤1 year before enrollment) and cardiovascular conditions to receive either early rhythm control or usual care. Early rhythm control included treatment with antiarrhythmic drugs or atrial fibrillation ablation after randomization. Usual care limited rhythm control to the management of atrial fibrillation-related symptoms. The first primary outcome was a composite of death from cardiovascular causes, stroke, or hospitalization with worsening of heart failure or acute coronary syndrome; the second primary outcome was the number of nights spent in the hospital per year. The primary safety outcome was a composite of death, stroke, or serious adverse events related to rhythm-control therapy. Secondary outcomes, including symptoms and left ventricular function, were also evaluated.

RESULTS: In 135 centers, 2789 patients with early atrial fibrillation (median time since diagnosis, 36 days) underwent randomization. The trial was stopped for efficacy at the third interim analysis after a median of 5.1 years of follow-up per patient. A first-primary-outcome event occurred in 249 of the patients assigned to early rhythm control (3.9 per 100 person-years) and in 316 patients assigned to usual care (5.0 per 100 person-years) (hazard ratio, 0.79; 96% confidence interval, 0.66 to 0.94; P = 0.005). The mean (±SD) number of nights spent in the hospital did not differ significantly between the groups (5.8±21.9 and 5.1±15.5 days per year, respectively; P = 0.23). The percentage of patients with a primary safety outcome event did not differ significantly between the groups; serious adverse events related to rhythm-control therapy occurred in 4.9% of the patients assigned to early rhythm control and 1.4% of the patients assigned to usual care. Symptoms and left ventricular function at 2 years did not differ significantly between the groups.

CONCLUSIONS: Early rhythm-control therapy was associated with a lower risk of adverse cardiovascular outcomes than usual care among patients with early atrial fibrillation and cardiovascular conditions. (Funded by the German Ministry of Education and Research and others; EAST-AFNET 4 ISRCTN number, ISRCTN04708680; ClinicalTrials.gov number, NCT01288352; EudraCT number, 2010-021258-20.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Kirchhof P, Camm AJ, Goette A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020. PMID: 32865375. doi:10.1056/NEJMoa2019422

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。